

NHS organisation statement template

Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS.

Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically available from the published literature. NICE believes it is important to involve NHS organisations that are responsible for commissioning and delivering care in the NHS in the process of making decisions about how technologies should be used in the NHS.

To help you give your views, we have provided a template. The questions are there as prompts to guide you. You do not have to answer every question. Short, focused answers, giving a PCT perspective on the issues you think the committee needs to consider, are what we need.

About you

Your name: [REDACTED], [REDACTED]

Name of your organisation: Hampshire Primary Care Trust

Please indicate your position in the organisation:

[REDACTED] with responsibility for leading the public health team supporting commissioning:

- Public health support to commissioning services for the PCT in general?
- Public health support to commissioning services for the PCT specific to the condition for which NICE is considering this technology?

What is the expected place of the technology in current practice?

1. How is the condition currently treated in the NHS? Is there significant geographical variation in current practice? Are there differences in opinion between professionals as to what current practice should be? What are the current alternatives (if any) to the technology, and what are their respective advantages and disadvantages?

PCT response:

“We would hope to see the NICE guidance to make reference to the different types of this disease (chronic lymphocytic leukaemia and small lymphocytic lymphoma) alluded to in the scope.

We would hope to see clarification on the criteria (and timing) for commencing and discontinuing treatment including which has relevance given the prolonged nature of the disease.”

2. To what extent and in which population(s) is the technology being used in your local health economy?

- is there variation in how it is being used in your local health economy?
- is it always used within its licensed indications? If not, under what circumstances does this occur?
- what is the impact of the current use of the technology on resources?
- what is the outcome of any evaluations or audits of the use of the technology?
- what is your opinion on the appropriate use of the technology?

PCT Response

“Unable to comment”

Potential impact on the NHS if NICE recommends the technology

3. What impact would the guidance have on the delivery of care for patients with this condition?

PCT Response

“Depending on the recommendation we would want to see reference to robust evidence on clinical and cost effectiveness and cost effectiveness modelling taking into account the different patterns of disease (chronic lymphocytic leukaemia and small lymphocytic lymphoma).”

4. In what setting should/could the technology be used – for example, primary or secondary care, specialist clinics? Would there be any requirements for additional resources (for example, staff, support services, facilities or equipment)?

PCT Response

“Unable to comment.”

5. Can you estimate the likely budget impact? If this is not possible, please comment on what factors should be considered (for example, costs, and epidemiological and clinical assumptions).

PCT Response

“Without the final guidance with recommendations this would be difficult. It would be very helpful if NICE could present a breakdown of anticipated patient numbers and potential drug and infrastructure costs for each PCT in England to inform planning any development.

Guidance on whether the treatment (if approved) was to time of progression (NICE to define please), or time of death would be helpful for commissioners.”

6. Would implementing this technology have resource implications for other services (for example, the trade-off between using funds to buy more diabetes nurses versus more insulin pumps, or the loss of funds to other programmes)?

PCT Response

“Quite possibly.”

7. Would there be any need for education and training of NHS staff?

PCT Response

“Probably”

Other Issues

Please include here any other issues you would like the Appraisal Committee to consider when appraising this technology.

PCT Response

“We would like to see safety issues robustly presented and considered in the light of recent FDA warnings about infusion related reactions and deaths.”